The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2021 | CAR-T and allo-SCT: landscape for myeloma and DLBCL
Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the current landscape of chimeric antigen receptor T-cell (CAR-T) therapy in the context of stem cell transplantation (SCT) for patients with multiple myeloma or diffuse large B-cell lymphoma (DLBCL). Prof. Kröger highlights upcoming results, comparing CAR-T and autologous-SCT in patients with DLBCL. Prof. Kröger shares that he anticipates an increase in the use of CAR-T in both advanced-stage and early-stage multiple myeloma in the near future. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
